Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (281-290 of 394) with videos related to

Pageof 40
Sort By:
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
The Journal of Clinical and Aesthetic Dermatology|June 20, 2025
Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement StudyGretchen D Ball, Hassan Hamade, Sarah Romanelli, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
JAMA Dermatology|January 21, 2026
Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine InhibitorMaria C Schneeweiss, Richard Wyss, Priyanka Anand, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
The Journal of Rheumatology|April 16, 2022
2021 GRAPPA Meet the Experts Session: A Summary of PresentationsApril W Armstrong, Rasika M Reddy, Oliver FitzGerald, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Pustular Psoriasis and Associated Musculoskeletal DisordersKristina Callis Duffin, Hervé Bachelez, Philip J Mease, et al.
Pageof 40

Showing results (281-290 of 394) with videos related to

Sort By:
Pageof 40
Arthritis Research & Therapy|December 28, 2022
Quantification of pre-existing radiographic damage and its relationship with joint activity and long-term clinical outcomes with secukinumab therapy in patients with psoriatic arthritisPhilip Mease, Désirée van der Heijde, Bruce Kirkham, et al.
The Journal of Clinical and Aesthetic Dermatology|June 20, 2025
Feasibility of IDEOM's Clinical Framework to Optimize Psoriatic Arthritis Care: A Cross-sectional Quality Improvement StudyGretchen D Ball, Hassan Hamade, Sarah Romanelli, et al.
Journal of Drugs in Dermatology : JDD|August 16, 2017
The Static Physician's Global Assessment of Genitalia: A Clinical Outcome Measure for the Severity of Genital PsoriasisJoseph F Merola, Alison Potts Bleakman, Alice B Gottlieb, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|December 10, 2025
Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasisJoseph F Merola, Lyn Guenther, Charles Lynde, et al.
JAMA Dermatology|January 21, 2026
Risk of Acne in Patients With Atopic Dermatitis Starting a JAK Inhibitor vs Th2 Cytokine InhibitorMaria C Schneeweiss, Richard Wyss, Priyanka Anand, et al.
JAMA Dermatology|May 11, 2022
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical TrialsKenneth B Gordon, Richard G Langley, Richard B Warren, et al.
The Journal of Rheumatology|April 16, 2022
2021 GRAPPA Meet the Experts Session: A Summary of PresentationsApril W Armstrong, Rasika M Reddy, Oliver FitzGerald, et al.
Journal of the American Academy of Dermatology|April 8, 2024
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trialsMark Lebwohl, Joseph F Merola, Bruce Strober, et al.
American Journal of Clinical Dermatology|August 31, 2025
Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb StudiesJoseph F Merola, Richard B Warren, Diamant Thaçi, et al.
The Journal of Rheumatology. Supplement|June 2, 2021
Pustular Psoriasis and Associated Musculoskeletal DisordersKristina Callis Duffin, Hervé Bachelez, Philip J Mease, et al.
Pageof 40